GSK’s focus on its R&D pipeline has come into play amidst the ongoing pandemic, with long-acting HIV drug, Cabotegravir (approval likely in H1 21) showcasing superior clinical efficacy over market-leader Gilead’s Truvada. Even in the myeloma-space, belantamab mafodotin, has received a positive recommendation from ODAC, despite some safety concerns. While both of these drugs could face intense competition, efficacy profiles should ensure market share gains in their respective s
16 Jul 2020
Spark in the pharma pipeline
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Spark in the pharma pipeline
GSK plc (GSK:LON) | 1,600 248 1.0% | Mkt Cap: 66,308m
- Published:
16 Jul 2020 -
Author:
Rishabh Kochar -
Pages:
2
GSK’s focus on its R&D pipeline has come into play amidst the ongoing pandemic, with long-acting HIV drug, Cabotegravir (approval likely in H1 21) showcasing superior clinical efficacy over market-leader Gilead’s Truvada. Even in the myeloma-space, belantamab mafodotin, has received a positive recommendation from ODAC, despite some safety concerns. While both of these drugs could face intense competition, efficacy profiles should ensure market share gains in their respective s